New Drug Class Established as Nuplazid Receives FDA Approval for Parkinson’s Disease Psychosis

From NeurologyWire

The FDA has approved Nuplazid (pimavanserin) from Acadia Pharmaceuticals for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis, which affects roughly 40 percent of patients with Parkinsons disease. The first FDA-approved medicine for this indication, Nuplazid preferentially targets 5-HT2A receptors (which ar...

Login to read story

Wednesday, March 23, 2016

Show last days of articles

Mobile Stroke Unit with Advanced CT Imaging Capabilities Lau...

From NeurologyWire

The University of Tennessee College of Medicine in Memphis, Tenn. recently introduced a comprehensive mobile stroke unit capable of conducting and pro...Full story

PCORI Seeking Advisory Panel Members

From NeurologyWire

The Patient-Centered Outcomes Research Institute (PCORI) has openings for researchers, clinicians and others on seven Advisory Panels and has extended...Full story

Epilepsy Drug Using 3D Printing Technology Now Available

From NeurologyWire

Spritam (levetiracetam, Aprecia Pharmaceuticals), the FDA-approved oral drug using novel 3D printing technology, is now available as an adjunctive the...Full story

Friday, March 18, 2016

FDA Approves Orchid Pharma's Generic Rasagiline

From NeurologyWire

Orchid Pharma Ltd. has received final approval from the FDA for its ANDA (Abbreviated New Drug Application) for Rasagiline Tablets 0.5mg and 1mg. This...Full story

Thursday, March 17, 2016

Human Stem Cells Used to Target Huntingtons Disease

From NeurologyWire

A new approach using stem cells may yield diminished neuron loss, reduced symptoms, and extended life in Huntingtons disease, new research suggests. A...Full story

Tuesday, March 15, 2016

InfoRx App from Vivacare Enables Neurologists to Deliver Per...

From Vivacare

The new InfoRx mobile app, recently released from Vivacare , enables neurologists to deliver personalized patient handouts, videos and other education...Full story

Monday, March 14, 2016

Investigational Cannabidiol Reduces Seizures in Patients wit...

From NeurologyWire

GW Pharmaceuticals unveiled positive results from its pivotal Phase 3 study of its investigational medicine Epidiolex (cannabidiol or CBD) for the tre...Full story

Friday, March 11, 2016

Friday, March 04, 2016

Sage Bionetworks Releases Novel Data from Parkinsons iPhone ...

From NeurologyWire

Data from an iPhone app may help scientists better understand Parkinsons disease. Sage Bionetworks, a nonprofit biomedical research organization, rele...Full story

Thursday, March 03, 2016

FDA Approves Medtronic Surgical Leads to Assist with Neurost...

From NeurologyWire

The FDA has approved Medtronic Specify SureScan MRI Surgical Leads for use as part of Medtronic implanted neurostimulation systems for chronic pain. I...Full story

Wednesday, March 02, 2016

Patient Enrollment Begins on Largest Brain Amyloid Scanning ...

From NeurologyWire

Participating dementia specialists may now enroll patients to participate in the Imaging DementiaEvidence for Amyloid Scanning (IDEAS) Study at IDEAS-...Full story

Friday, February 19, 2016

FDA Approves UCB's Briviact (brivaracetam) for Partial-onset...

From NeurologyWire

UCB has received FDA for BRIVIACT (brivaracetam) as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and olde...Full story

Edge Therapeutics Presents Positive Data for Aneurysmal Suba...

From NeurologyWire

At the International Stroke Conference in Los Angeles, Edge Therapeutics, Inc. presented positive data supporting the potential pharmacoeconomic impac...Full story

Thursday, February 18, 2016

Codman Neuro Unveils Vascular Reconstruction Device for Wide...

From NeurologyWire

Codman Neuro has launched the Codman Enterprise 2 Vascular Reconstruction Device, the latest generation of the companys self-expanding stent and deliv...Full story